UK’s QuantuMDx Invests £11M To Bring Forward Launch Of Rapid, Point-Of-Care DNA Analyzer
The COVID-19 pandemic has accelerated development of another new molecular diagnostic technology.
You may also be interested in...
As far as aspirations go, QuantuMDx is setting its sights high. The UK diagnostics start-up is still in the early stages of product development but one thing CEO Elaine Warburton has set her mind on is ensuring the company’s “lab-in-your-hand” device will emulate the sleek, simple and user-friendly designs that are iconic of the information technology giant Apple.
The UK-based company is seeking to raise a further $100m in 2021 following the recent US clearance of its first product, a daytime-use neurostimulation device for snoring and mild obstructive sleep apnea.
The deal combines two of the largest providers of sterilization and infection-prevention products to create a $4bn-plus-revenue business.